Broad approach needed against pharmaceutical residues in environment We can all help to reduce pollution of the environment by pharmaceutical residues.
Icy air measurements Bernice Notenboom’s Arctic March expedition team has reached the summit of Greenland. She has conquered the 3500-metre high summit on Greenland with functioning air measuring equipment.
Vaccination using needles: there are alternatives Dr Hoang Hirschberg, employed at RIVM, has carried out PhD research into three alternatives for needle injections. She concluded that all alternatives have advantages and limitations.
Injection needles: fact-finding and risk assessment of excess adhesive Commissioned by the Dutch Health Care Inspectorate (IGZ), RIVM investigated whether excess adhesive is present in two types of injection needles from the Terumo Company (K-Pack II and Neolus).
Points of special interest in home treatment with complex medical technologies Patients are increasingly being treated with complex medical technologies in their own home. This offers great benefits, however, it also introduces risks.
Climate reporter Bernice Notenboom arrives in Greenland for continuation of climate expedition Climate reporter and expedition leader Bernice Notenboom and her team left for Greenland on 4 May 2015 for the second part of the Arctic March.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
Breast milk as indicator of environmental pollutants The 6th worldwide study into Persistent Organic Pollutants (POPs) in breast milk is about to commence.
The National Immunisation Programme in the Netherlands: Developments in 2013 Annually RIVM provides an overview of key events and developments in the National Immunisation Programme (NIP).
New RIVM-method used to detect influenza A (H7H9) population immunity The level of immunity to the recently circulating H7N9 influenza virus in an urban and rural population in Vietnam is very low, according to the first population level study to examine human immuni